Key facts
- Cellula Therapeutics’s last known valuation is $13.9M (Jul 2025).
- It has raised $3.6M; the latest was Early Stage VC ($3.6M) in Jul 2025.
- Notable investors include Remora Biotech, University of Geneva.
- Status: Privately Held (backing).
Investors
2- ·The complete investor list — 2 names
- ·Watchlist + deal alerts for Cellula Therapeutics
- ·The full record, as it builds
Funding rounds
No funding rounds for Cellula Therapeutics are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Cellula Therapeutics
Developer of next-generation CAR-T cell therapies designed to cure solid tumours, specifically targeting aggressive brain cancers. The company offers armoured immune cell effectors that utilise breakthrough pathways, enabling clients to access transformative treatments for difficult-to-treat solid tumours.
- Sector
- Healthcare
- HQ
- Lausanne, Switzerland
- Founded
- 2023
- Employees
- 7
- Ownership
- Privately Held (backing)
Cellula Therapeutics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Cellula Therapeutics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Cellula Therapeutics in its N-PORT filings yet. We sweep new filings monthly.